Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
NCT02862132
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
142
Enrollment
OTHER
Sponsor class
Conditions
Crohn's Disease
Ulcerative Colitis
Inflammatory Bowel Disease
Interventions
DRUG:
Vedolizumab
Sponsor
Shaare Zedek Medical Center